Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2025 | Melanoma at ESMO 2025: SWOG S1801, NADINA, and more

Alexander van Akkooi • 18 Oct 2025
ESMO 2025
Melanoma Skin Cancer Antibodies

Alexander van Akkooi, MD, PhD, Melanoma Institute Australia, Sydney, Australia, discusses the upcoming melanoma abstracts 2025 European Society for Medical Oncology (ESMO) conference, including the SWOG S1801 (NCT03698019) and NADINA (NCT04949113) studies. Dr van Akkooi also mentions the potential for de-escalation studies in the advanced setting, allowing for tailored treatment and potentially stopping treatment earlier in responding patients. This interview took place at the ESMO 2025 Congress in Berlin, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Alexander van Akkooi

Primary analysis of Columbus-AD: encorafenib and binimetinib in high-risk stage II melanoma
1:43
Primary analysis of Columbus-AD: encorafenib and binimetinib in high-risk stage II melanoma
Alexander van Akkooi • 30 May 2025
Importance of minimal sentinel node tumor burden in melanoma staging
0:31
Importance of minimal sentinel node tumor burden in melanoma staging
Alexander van Akkooi • 14 Sep 2024
The evolving role of surgery after neoadjuvant immunotherapy in melanoma
0:50
The evolving role of surgery after neoadjuvant immunotherapy in melanoma
Alexander van Akkooi • 15 Sep 2024
EORTC 1208 Minitub: a prospective registry of patients with SN positive melanoma
0:47
EORTC 1208 Minitub: a prospective registry of patients with SN positive melanoma
Alexander van Akkooi • 14 Sep 2024

Related Videos

BRAF/MEK inhibition prior to immunotherapy in melanoma: insights from the COWBOY trial
1:45
BRAF/MEK inhibition prior to immunotherapy in melanoma: insights from the COWBOY trial
Kalijn Bol • 31 May 2026
COWBOY trial: optimal sequencing of BRAF/MEK inhibition and immunotherapy in BRAF-mutated melanoma
1:08
COWBOY trial: optimal sequencing of BRAF/MEK inhibition and immunotherapy in BRAF-mutated melanoma
Kalijn Bol • 31 May 2026
Could induction BRAF/MEK inhibition be useful for some melanoma patients with metastases?
1:02
Could induction BRAF/MEK inhibition be useful for some melanoma patients with metastases?
Kalijn Bol • 31 May 2026
The future of personalized and off-the-shelf mRNA vaccines in melanoma
1:02
The future of personalized and off-the-shelf mRNA vaccines in melanoma
James Smithy • 31 May 2026
The content of VJOncology is intended for healthcare professionals